Wall Street Zen cuts NVCR to Hold despite raised guidance
Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash
Wall Street Zen has downgraded Novocure stock from Buy to Hold, citing a consensus target of USD 21.20. This comes after Novocure reported a 16% year-over-year increase in Q2 2026 revenue to USD 184.00 million and raised its full-year 2026 revenue guidance. The company also saw FDA approval for Optune Pax for pancreatic cancer and will report Q3 2026 results on October 29, 2026.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.